Ignite Creation Date:
2025-12-24 @ 4:04 PM
Ignite Modification Date:
2026-02-23 @ 1:52 PM
Study NCT ID:
NCT06454266
Status:
COMPLETED
Last Update Posted:
2024-07-30
First Post:
2024-05-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)
Sponsor:
Ningbo No. 1 Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Central Nervous System Lymphoma | View |
Keywords: